<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890419</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102106</org_study_id>
    <nct_id>NCT03890419</nct_id>
  </id_info>
  <brief_title>Opioid Sparing Potential of Light-Induced Analgesia</brief_title>
  <official_title>Opioid Sparing Potential of Light-Induced Analgesia: a Pilot Trial of a Novel, Non-Pharmacological Treatment for Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot trial testing the potential opioid-sparing analgesic effect of a novel
      non-pharmacological treatment using visualized light spectrums. Preclinical findings have
      shown such treatments to alter pain perception.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Level</measure>
    <time_frame>Day 1, Week 1 and approximately Week 2 (chronic pain) or 48 hours (acute pain)</time_frame>
    <description>We will assess the patients pain level using the Numeric Rating Scale.In a Numerical Rating Scale (NRS), patients are asked to circle the number between 0 and 10 that fits best to their pain intensity . Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Opioid dose used for pain</measure>
    <time_frame>Day 1, Week 1 and approximately Week 2 (chronic pain) or 48 hours (acute pain)</time_frame>
    <description>We will measure the amount of opioid medication used for pain relief. This will be measure in oral morphine equivalents.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Group participants will be exposed to full spectrum light during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Green light Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green light Group participants will be exposed to green light during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blue light Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blue light Group participants will be exposed to green light during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Green light</intervention_name>
    <description>Green light exposure</description>
    <arm_group_label>Green light Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clear light</intervention_name>
    <description>Full spectrum light exposure</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blue Light</intervention_name>
    <description>Blue light exposure</description>
    <arm_group_label>Blue light Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for thoracic surgery for which post-operative opioid PCA is anticipated
             (Acute Pain group) OR currently treated with opioid therapy for fibromyalgia (Chronic
             Pain group)

          -  18 years of age and older

          -  Able to wear study eyeglasses for at least 4 hours per day

          -  Agree to participate and provide written informed consent and HIPAA authorization

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padma Gulur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Nelli, MD</last_name>
    <phone>919-681-4988</phone>
    <email>amanda.nelli@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Health Systems</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Nelli, MD</last_name>
      <phone>919-861-4988</phone>
      <email>amanda.nelli@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Pain</keyword>
  <keyword>Chronic Pain</keyword>
  <keyword>Opioid Use</keyword>
  <keyword>Pain</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

